New York, NY–(ENEWSPF)–March 29, 2012. The activation of specific endogenous cannabinoid receptors moderates the progression of the human immunodeficiency virus (HIV), according to preclinical data published online in the journal PLoS ONE.
Investigators at the Mount Sinai School of Medicine in New York City assessed whether the administration of a selective cannabinoid agonist could regulate HIV-1 infectivity. Researchers reported that activation of the CB2 receptor inhibits HIV infection in culture.
Authors concluded, “[T]he clinical use…
